Log in

Pharmaxis Ltd (PXS.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.09
52-Week Range N/A
Volume721,139 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual Sales$11.54 million
Book ValueA$0.00 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive PXS News and Ratings via Email

Sign-up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pharmaxis Ltd (PXS.AX) (ASX:PXS) Frequently Asked Questions

What stocks does MarketBeat like better than Pharmaxis Ltd (PXS.AX)?

Wall Street analysts have given Pharmaxis Ltd (PXS.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharmaxis Ltd (PXS.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Pharmaxis Ltd (PXS.AX)'s earnings last quarter?

Pharmaxis Ltd (PXS.AX) (ASX:PXS) announced its earnings results on Thursday, February, 14th. The company reported ($0.03) EPS for the quarter.
View Pharmaxis Ltd (PXS.AX)'s earnings history

Who are some of Pharmaxis Ltd (PXS.AX)'s key competitors?

What other stocks do shareholders of Pharmaxis Ltd (PXS.AX) own?

Who are Pharmaxis Ltd (PXS.AX)'s key executives?

Pharmaxis Ltd (PXS.AX)'s management team includes the following people:
  • Mr. Gary Jonathan Phillips, CEO, MD & Director (Age 59, Pay $484.86k)
  • Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 64, Pay $400.08k)
  • Dr. Wolfgang G. Jarolimek Ph.D., B.Sc. Ph.D., Head of Drug Discovery (Age 56, Pay $393.82k)
  • Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs (Age 48, Pay $217.93k)
  • Dr. Brett Charlton Ph.D., MBBS Ph.D., Medical Director (Age 64, Pay $393.67k)
  • Mr. Cameron David Billingsley, Gen. Counsel (Age 43)
  • Dr. Dieter Hamprecht, Head of Chemistry for Drug Discovery

What is Pharmaxis Ltd (PXS.AX)'s stock symbol?

Pharmaxis Ltd (PXS.AX) trades on the ASX under the ticker symbol "PXS."

How big of a company is Pharmaxis Ltd (PXS.AX)?

Pharmaxis Ltd (PXS.AX) has a market capitalization of $0.00 and generates $11.54 million in revenue each year. Pharmaxis Ltd (PXS.AX) employs 69 workers across the globe.

What is Pharmaxis Ltd (PXS.AX)'s official website?

The official website for Pharmaxis Ltd (PXS.AX) is www.pharmaxis.com.au.

How can I contact Pharmaxis Ltd (PXS.AX)?

Pharmaxis Ltd (PXS.AX)'s mailing address is 20 Rodborough Rd, FRENCHS FOREST, NSW 2086, Australia. The company can be reached via phone at +61-2-94547200.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.